Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)
OTCMKTS · Delayed Price · Currency is USD
9.36
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
SBLOF Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | 15,408 | 12,032 | 10,274 | 10,533 | 6,628 | 7,230 |
Short-Term Investments | - | - | 336 | - | 368 | 55 |
Cash & Short-Term Investments | 15,408 | 12,032 | 10,610 | 10,533 | 6,996 | 7,285 |
Cash Growth | 53.20% | 13.40% | 0.73% | 50.56% | -3.97% | 38.79% |
Receivables | 4,953 | 6,513 | 5,722 | 4,695 | 3,499 | 2,952 |
Inventory | 15,756 | 12,618 | 12,373 | 7,329 | 4,359 | 4,071 |
Other Current Assets | 1,704 | 1,776 | 2,132 | 1,342 | 1,280 | 472 |
Total Current Assets | 37,821 | 32,939 | 30,837 | 23,899 | 16,134 | 14,780 |
Property, Plant & Equipment | 36,082 | 34,832 | 26,357 | 18,879 | 13,155 | 12,897 |
Long-Term Investments | 34,438 | 20,469 | 15,926 | 12,404 | 8,645 | 8,522 |
Goodwill | 1,764 | 1,884 | 1,934 | 1,438 | - | - |
Other Intangible Assets | 272.83 | 219 | 225 | 261 | 212 | 213 |
Long-Term Deferred Tax Assets | - | 2,036 | 989 | 325 | 1,129 | 521 |
Other Long-Term Assets | 2,703 | 2 | 2 | 2 | 1 | 2 |
Total Assets | 113,081 | 92,416 | 76,302 | 57,242 | 39,312 | 36,972 |
Accounts Payable | 758.97 | 460 | 460 | 419 | 64 | 95 |
Short-Term Debt | 18,670 | 11,777 | 7,826 | 8,923 | 2,942 | 3,486 |
Current Income Taxes Payable | 302.78 | 2,217 | 1,701 | 603 | 743 | 683 |
Other Current Liabilities | 15,249 | 14,802 | 13,580 | 11,066 | 9,624 | 7,651 |
Total Current Liabilities | 34,981 | 29,256 | 23,567 | 21,011 | 13,373 | 11,915 |
Long-Term Debt | 22,371 | 22,271 | 18,147 | 9,480 | 5,809 | 8,669 |
Long-Term Leases | 482.88 | 425 | 212 | 357 | 385 | 529 |
Long-Term Deferred Tax Liabilities | - | 235 | 84 | - | - | - |
Other Long-Term Liabilities | 2,040 | 145 | 133 | 36 | 22 | 20 |
Total Liabilities | 59,874 | 52,332 | 42,143 | 30,884 | 19,589 | 21,133 |
Common Stock | 9,679 | 9,679 | 9,679 | 9,679 | 9,679 | 9,679 |
Additional Paid-In Capital | 2,399 | 2,358 | 2,358 | 2,306 | 2,306 | 2,306 |
Retained Earnings | 20,277 | 20,087 | 17,215 | 13,766 | 10,196 | 3,854 |
Comprehensive Income & Other | 20,505 | 7,898 | 4,861 | 460 | -2,620 | -104 |
Total Common Equity | 52,859 | 40,022 | 34,113 | 26,211 | 19,561 | 15,735 |
Minority Interest | 348.31 | 62 | 46 | 147 | 162 | 104 |
Shareholders' Equity | 53,207 | 40,084 | 34,159 | 26,358 | 19,723 | 15,839 |
Total Liabilities & Equity | 113,081 | 92,416 | 76,302 | 57,242 | 39,312 | 36,972 |
Total Debt | 41,523 | 34,473 | 26,185 | 18,760 | 9,136 | 12,684 |
Net Cash (Debt) | -26,116 | -22,441 | -15,575 | -8,227 | -2,140 | -5,399 |
Net Cash Per Share | -627.30 | -539.05 | -374.12 | -197.62 | -51.40 | -129.68 |
Filing Date Shares Outstanding | 41.63 | 41.63 | 41.63 | 41.63 | 41.63 | 41.63 |
Total Common Shares Outstanding | 41.63 | 41.63 | 41.63 | 41.63 | 41.63 | 41.63 |
Working Capital | 2,840 | 3,683 | 7,270 | 2,888 | 2,761 | 2,865 |
Book Value Per Share | 1269.67 | 961.33 | 819.40 | 629.59 | 469.85 | 377.95 |
Tangible Book Value | 50,822 | 37,919 | 31,954 | 24,512 | 19,349 | 15,522 |
Tangible Book Value Per Share | 1220.74 | 910.82 | 767.54 | 588.78 | 464.76 | 372.84 |
Order Backlog | - | 35,690 | 34,404 | 29,249 | 19,724 | 13,447 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.